
Precipio PRPO
$ 27.5
0.0%
Quarterly report 2025-Q3
added 11-14-2025
Precipio EV - Enterprise Value 2011-2026 | PRPO
Annual EV - Enterprise Value Precipio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.9 M | 2.47 M | 26.4 M | 49.4 M | 16.4 M | 19.3 M | 19.1 M | 36.7 M | 25.1 M | 49.9 M | 17.2 M | 14 M | 17.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 49.9 M | 2.47 M | 23.4 M |
EV - Enterprise Value of other stocks in the Diagnostics research industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-19.1 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
1.64 B | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
223 M | $ 13.65 | - | $ 99.4 M | ||
|
Castle Biosciences
CSTL
|
665 M | $ 25.83 | - | $ 717 M | ||
|
Aspira Women's Health
AWH
|
42.8 M | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
28.2 B | $ 66.34 | - | $ 25.9 B | ||
|
Bioventus
BVS
|
1.01 B | $ 8.87 | - | $ 591 M | ||
|
Guardant Health
GH
|
15.2 B | $ 87.18 | 1.98 % | $ 10.9 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
26.2 M | - | - | $ 562 M | ||
|
Charles River Laboratories International
CRL
|
11.4 B | $ 151.97 | - | $ 7.53 B | ||
|
CareDx, Inc
CDNA
|
1.04 B | $ 17.32 | - | $ 923 M | ||
|
ICON Public Limited Company
ICLR
|
26.4 B | $ 97.61 | - | $ 8.05 B | ||
|
IQVIA Holdings
IQV
|
49.6 B | $ 164.89 | - | $ 28.3 B | ||
|
Accelerate Diagnostics
AXDX
|
92.6 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
22 B | $ 103.85 | - | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
-2.77 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
6.64 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
9.21 B | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
251 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
502 M | $ 14.95 | - | $ 452 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
5.02 B | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
142 M | $ 17.29 | - | $ 2.24 B | ||
|
Anixa Biosciences
ANIX
|
990 K | $ 2.84 | - | $ 92.2 K | ||
|
Neogen Corporation
NEOG
|
2.26 B | $ 9.11 | - | $ 1.98 B | ||
|
Danaher Corporation
DHR
|
145 B | $ 191.39 | - | $ 136 B | ||
|
Biocept
BIOC
|
15 M | - | -13.05 % | $ 7.29 M | ||
|
Pacific Biosciences of California
PACB
|
1.21 B | $ 1.36 | - | $ 408 M | ||
|
Heska Corporation
HSKA
|
851 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
3.16 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
15.3 B | $ 119.28 | - | $ 19 B | ||
|
Quest Diagnostics Incorporated
DGX
|
22.9 B | $ 198.94 | - | $ 22.1 B | ||
|
QIAGEN N.V.
QGEN
|
11.3 B | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
45.8 B | $ 111.83 | - | $ 34 B | ||
|
BioNano Genomics
BNGO
|
35.7 M | $ 1.11 | - | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
6.61 M | $ 8.42 | -6.44 % | $ 239 M | ||
|
Lantheus Holdings
LNTH
|
5.9 B | $ 78.5 | - | $ 5.3 B | ||
|
Chembio Diagnostics
CEMI
|
39.2 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
2.55 M | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
29.3 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
14 B | $ 453.64 | - | $ 13.1 B | ||
|
Twist Bioscience Corporation
TWST
|
1.55 B | $ 45.01 | - | $ 2.69 B | ||
|
Motus GI Holdings
MOTS
|
568 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
32.1 B | $ 1 198.71 | - | $ 24.7 B | ||
|
Celcuity
CELC
|
506 M | $ 114.9 | - | $ 4.53 B | ||
|
DermTech
DMTK
|
70.4 M | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
432 M | $ 17.4 | - | $ 389 M | ||
|
NeoGenomics
NEO
|
1.85 B | $ 8.24 | - | $ 1.06 B | ||
|
Invitae Corporation
NVTA
|
2.11 B | - | - | $ 21.2 M | ||
|
Enzo Biochem
ENZ
|
-22.7 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
5.53 B | $ 197.68 | - | $ 19.5 B |